BR112023023151A2 - Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes - Google Patents

Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes

Info

Publication number
BR112023023151A2
BR112023023151A2 BR112023023151A BR112023023151A BR112023023151A2 BR 112023023151 A2 BR112023023151 A2 BR 112023023151A2 BR 112023023151 A BR112023023151 A BR 112023023151A BR 112023023151 A BR112023023151 A BR 112023023151A BR 112023023151 A2 BR112023023151 A2 BR 112023023151A2
Authority
BR
Brazil
Prior art keywords
ionic liquid
inflammatory
autoimmune diseases
liquid formulations
treatment
Prior art date
Application number
BR112023023151A
Other languages
English (en)
Inventor
Kelly Ibsen
Tyler Brown
Original Assignee
I2O Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I2O Therapeutics Inc filed Critical I2O Therapeutics Inc
Publication of BR112023023151A2 publication Critical patent/BR112023023151A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes. a presente divulgação fornece composições compreendendo um agente terapêutico e pelo menos um líquido iônico e uso das mesmas para tratar condições ou doenças em um indivíduo. especificamente, a presente divulgação fornece um método de tratamento de doenças inflamatórias e autoimunes através da dispensação de formulações líquidas iônicas compreendendo colina como cátion e vários ânions; e um anticorpo terapêutico ou um reagente de anticorpo para um indivíduo.
BR112023023151A 2021-05-05 2022-05-05 Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes BR112023023151A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163184333P 2021-05-05 2021-05-05
PCT/US2022/027794 WO2022235882A1 (en) 2021-05-05 2022-05-05 Ionic liquid formulations for treating inflammatory and autoimmune diseases

Publications (1)

Publication Number Publication Date
BR112023023151A2 true BR112023023151A2 (pt) 2024-01-23

Family

ID=83932928

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023151A BR112023023151A2 (pt) 2021-05-05 2022-05-05 Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes

Country Status (10)

Country Link
US (1) US20240067716A1 (pt)
EP (1) EP4333891A1 (pt)
JP (1) JP2024518169A (pt)
KR (1) KR20240046687A (pt)
CN (1) CN117642180A (pt)
AU (1) AU2022270665A1 (pt)
BR (1) BR112023023151A2 (pt)
CA (1) CA3217942A1 (pt)
IL (1) IL308290A (pt)
WO (1) WO2022235882A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050557A1 (en) * 2014-05-23 2016-08-03 Ares Trading S.A. Liquid pharmaceutical composition
US10463733B1 (en) * 2016-10-04 2019-11-05 United States of America as represented by the Secetary of the Air Force Ultra-stable protein ionic liquids
US11608357B2 (en) * 2018-08-28 2023-03-21 Arecor Limited Stabilized antibody protein solutions
US11738068B2 (en) * 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
US20220144914A1 (en) * 2019-03-01 2022-05-12 President And Fellows Of Harvard College Methods and compositions for protein delivery

Also Published As

Publication number Publication date
CN117642180A (zh) 2024-03-01
WO2022235882A1 (en) 2022-11-10
AU2022270665A1 (en) 2023-12-07
IL308290A (en) 2024-01-01
EP4333891A1 (en) 2024-03-13
KR20240046687A (ko) 2024-04-09
CA3217942A1 (en) 2022-11-10
US20240067716A1 (en) 2024-02-29
JP2024518169A (ja) 2024-04-25

Similar Documents

Publication Publication Date Title
BR112014016672A2 (pt) compostos de carbamato e sua preparação e uso
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
BR112019008458A2 (pt) 1,2,4-triazolonas 2,4,5-trisubstituídas.
BR112022002150A2 (pt) Composições e métodos para tratar psoríase e dermatite atópica com o uso de prevotella histicola
BR112013018920A2 (pt) composições de nanopartículas, formulações destas e seus usos
BR112014028633A8 (pt) tratamento de amd usando sflt-1 de aav
BR112015021392A2 (pt) uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas
BR112016022318A2 (pt) método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo
BR112014014783A2 (pt) moléculas de inibidor de jnk para tratamento de várias doenças
BR112016018205A8 (pt) métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente
MX2019002377A (es) Composicion y metodos para la prediccion de la actividad de la enzastaurina.
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
BRPI0511398A (pt) composição farmacêutica anidra para o tratamento da psorìase e uso de um agente siliconado
BR112018014467A2 (pt) tecnologia de sinergismo fármaco-anticorpo para o tratamento de doenças
BR112014010594A2 (pt) terapia genética para neuropatia diabética empregando um isoforma do hgf
CO2022013055A2 (es) Tafoxiparina para el tratamiento de la preeclampsia
BR112019006174A2 (pt) proteina terapêutica
CO2023005057A2 (es) Compuestos y composiciones como moduladores de señalización tlr
BR112021017957A2 (pt) Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo
BR112013011064A2 (pt) uso cosmético nutracêutico ou oral e processo de tratamento cosmético oral
BR112023023151A2 (pt) Formulações líquidas iônicas para tratamento de doenças inflamatórias e autoimunes
BR112014012966A2 (pt) método para o controle da proliferação de pseudomonas; e uso de um agente de desinfecção
BR112021018918A2 (pt) Compostos e composições como moduladores de sinalização de tlr
BR112018067967A2 (pt) tratamento de pacientes com hipercolesterolemia familiar homozigótica por meio de terapia hipolipemiante